201 related articles for article (PubMed ID: 23382304)
1. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
Itoh S; Matsuoka H; Yasuda Y; Miyake N; Suzuki K; Yorifuji T; Sugihara S
J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
[TBL] [Abstract][Full Text] [Related]
2. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
Doneray H; Houghton J; Tekgunduz KS; Balkir F; Caner I
J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
[TBL] [Abstract][Full Text] [Related]
3. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
[TBL] [Abstract][Full Text] [Related]
4. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
[TBL] [Abstract][Full Text] [Related]
5. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.
Gloyn AL; Diatloff-Zito C; Edghill EL; Bellanné-Chantelot C; Nivot S; Coutant R; Ellard S; Hattersley AT; Robert JJ
Eur J Hum Genet; 2006 Jul; 14(7):824-30. PubMed ID: 16670688
[TBL] [Abstract][Full Text] [Related]
6. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
[TBL] [Abstract][Full Text] [Related]
7. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.
Peña-Almazan S
Diabetes Res Clin Pract; 2015 Apr; 108(1):e18-20. PubMed ID: 25678012
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
[TBL] [Abstract][Full Text] [Related]
9. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
[TBL] [Abstract][Full Text] [Related]
10. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
[No Abstract] [Full Text] [Related]
11. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
[TBL] [Abstract][Full Text] [Related]
12. Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function.
Gurgel LC; Crispim F; Noffs MH; Belzunces E; Rahal MA; Moisés RS
Diabetes Care; 2007 Nov; 30(11):e108. PubMed ID: 17965292
[No Abstract] [Full Text] [Related]
13. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
[No Abstract] [Full Text] [Related]
14. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.
Koster JC; Cadario F; Peruzzi C; Colombo C; Nichols CG; Barbetti F
J Clin Endocrinol Metab; 2008 Mar; 93(3):1054-61. PubMed ID: 18073297
[TBL] [Abstract][Full Text] [Related]
15. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
Mohamadi A; Clark LM; Lipkin PH; Mahone EM; Wodka EL; Plotnick LP
Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
[TBL] [Abstract][Full Text] [Related]
16. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
[TBL] [Abstract][Full Text] [Related]
18. Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Della Manna T; Battistim C; Radonsky V; Savoldelli RD; Damiani D; Kok F; Pearson ER; Ellard S; Hattersley AT; Reis AF
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1350-5. PubMed ID: 19169493
[TBL] [Abstract][Full Text] [Related]
19. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds.
Zhang M; Chen X; Shen S; Li T; Chen L; Hu M; Cao L; Cheng R; Zhao Z; Luo F
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):877-84. PubMed ID: 25781672
[TBL] [Abstract][Full Text] [Related]
20. Sulfonylurea-responsive diabetes in childhood.
Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
